Short BiographyI graduated in Biochemistry from the National University of La Plata, Argentina in 1982. I pursued my post-graduate studies under the supervision of Dr Fernando Estivariz at the Faculty of Medicine, National University of La Plata and obtained my PhD in 1986. I then pursued post-doctoral training under the supervision of Dr Peng Loh at the National Institues of Child Health and Human Development/NIH, USA were I was engaged in research related to understanding the molecular and cellular mechanisms of regulated hormone secretion in eukaryotic cells. I moved to England in 1989 were I pursued further post-doctoral studies, under the mentorship of Professor Phil Lowry. My research project aimed to elucidate the biological activity and post-translational processing of pro-hormone precursors. In 1992 I obtained my first independent academic/research position at the University of Wales, College of Cardiff as Assistant Professor of Physiology. In 1995 I moved to The University of Manchester were I was promoted to Associate Professor and later to Full Professor in the School of Medicine. During my tenure at the University of Manchester,I co-directed the Molecular Medicine and Gene Therapy Unit. I moved back to the USA in 2001, to co-direct the Gene Therapeutics Research Institute at Cedars Sinai Medical Center and I became Full Professor of Medicine and Full Professor of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA. My research program aims to understand the molecular and cellular immune mechanisms which mediate tumor regression in response to therapeutic interventions which aim at modifying the tumor micro-environment. We have developed stringent in vivo preclinical models to assess trafficking of immune cells into the tumor mass, tumor specific T cell expansion, antigen presentation and mechanisms which mediate anti-tumor immunological memory. We aim to translate these findings into clinical trials for both primary and metastatic brain cancer patients.
Research Areascancer immunotherapies; neuro-immunology; gene therapy; brain cancer; giloma; trafficking of immune cells in vivo; tumor microenvironment